Navigation Links
Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
Date:9/15/2011

BOSTON, Sept. 15, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company has shown a 32% increase in Breast Endoscopy sales for the period of June through August 2011 as compared to the prior year.  Management recently reported an increase in demand for its new MammoView® instrument line.  

The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

Sales of Breast Endoscopy Components for the period of June through August 2011 were $51,630, which represents a 32% increase from the prior year.  The Solos MammoView® instrument line is featured on the Company's new website www.solosendoscopy.com.  

"The fact that we have taken this tremendous product from concept phase to sales in dozens of hospitals across the Country is extremely gratifying.  We expect to see continued sales improvement in the 4th Quarter" stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

CONTACT: Amanda Segersten, rsegersten@solosendoscopy.com


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy to Reduce Debt by Over $620,000
2. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
3. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
4. Solos Endoscopy, Inc. To Launch New Corporate Website
5. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
6. Solos Endoscopy, Inc. To Introduce New Urology Instrument Line
7. Solos Endoscopy, Inc. Reports $34,291 in Sales Revenue for January 2011
8. Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
9. Solos Endoscopy, Inc. Trends toward Strong Continued Growth in 2011
10. Solos Endoscopy, Inc. Announces Recapitalization Plan for 2011
11. Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Calif. , March 24, 2017 /PRNewswire/ ... epigenetics company, and Hamilton Robotics, Inc., who ... announced an ongoing collaboration that teams Zymo ... and RNA and DNA extraction products with ... already created optimized methods for microbiomics and ...
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... to their offering. ... IPF pipeline is very strong with a total of 97 drug candidates. ... and Sanofi are involved in the development of the IPF therapeutics. The ... Phase III stage, 15 are in Phase II stage, 12 are in ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, ... Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare would ... estimates a reduction in employer-based coverage due to the GOP reform, which is not ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . ... for the product – with nearly 2,000 consumers (and counting) already backing the ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to ... critical historical facts, cultural practices, goods, services, and societal issues tend to appreciate and ... into the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “End Time GPS”: ... salient events will interrelate. “End Time GPS” is the creation of published author, ... expert while working on military munitions and space-vehicle projects. Now, at age ninety-one, he ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National ... preparation programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT ... teacher quality in the U.S. It argues that this higher bar should be set ...
Breaking Medicine News(10 mins):